Frequency of germline mutations in BRCA1 and BRCA2 in ovarian cancer patients and their effect on treatment outcome.

Cancer Manag Res · 2019 · PMC6626894 · PMID 31372034

Europe PMC DOI

hedged sentence

0.0800

closest p · 1.6× alpha

0.0800

boldest claim

The sentences

approached significanceP =0.08so close (0.05 < p ≤ 0.1)

Patients carrying pathogenic BRCA1/2 mutations had a median PFS of 42.43 months (95% CI 32.04–52.83), which was longer than the median PFS of 22.24 months (95% CI 14.83–29.58) in non-carriers; this difference approached significance ( P =0.08) ( Figure 1 ).

also in 8,237 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.